H
eart failure (HF) is a global public health problem with an estimated prevalence of 38 million worldwide. 1 Clinical outcomes for many of these patients remain poor and similar to many cancers, justifying the continued need for ongoing development of drug and device therapies. 2 To successfully execute the large outcome studies necessary to definitively test such treatments, phase III HF trials have experienced a rapid trend toward globalization in recent years. [3] [4] [5] Although inclusion of multiple global populations fosters inclusive and collaborative research, recent globalization trends may be mostly driven by study execution considerations and the need to efficiently enroll large patient populations in a reasonable time frame. [5] [6] [7] Despite uniform selection criteria, existing trial data strongly suggest that patients hospitalized for HF vary markedly by geographic region of enrollment. [8] [9] [10] [11] [12] The precise mechanism(s) by which region influences patient profile and event rates is unknown, but it is plausible that country income status may be an important mediator of these differences. Consistent with movement toward trial globalization, recent HF studies have consistently included patients from both high-income and lower income countries. On one hand, less-developed areas may be appealing from a cost and regulatory standpoint and often provide higher enrollment rates than centers from high-income countries. 13 However, these benefits toward enrollment may be balanced against potential quality control issues. 14 To our knowledge, the question of whether country income status influences patient characteristics, downstream patient protocol completion rates, and HF trial end points has not been specifically studied. Likewise, the influence of country income status independent of geographic region is unclear. In this context, the global ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) database provides an opportunity to better understand these relationships and rigorously characterize the correlation between enrolling country income status, patient characteristics, protocol completion, and trial end points.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Design
The design and primary results of the ASCEND-HF trial have been published previously. 15, 16 Briefly, ASCEND-HF was a prospective, multinational, randomized, placebo-controlled trial studying the effects of nesiritide on dyspnea relief and clinical outcomes among patients hospitalized for acute HF (AHF) with either reduced or preserved ejection fraction. Eligible patients were enrolled within 24 hours of first intravenous HF therapy, had dyspnea at rest or with minimal exertion, ≥1 clinical sign of HF, and ≥1 objective measure of HF. The trial was conducted in accordance with the Declaration of Helsinki and with institutional review board/ethics committee approval at all sites. All patients provided written informed consent.
Geographic Region and Country Income Level
The ASCEND-HF trial enrolled 7141 patients at 398 sites across 30 countries in North America, Latin America, Western Europe, Central Europe, and Asia-Pacific between May 2007 and August 2010. Per trial protocol, geographic regions were defined as follows: North America-Canada, United States; Latin America-Argentina, Brazil, Chile, Colombia, Mexico; Western Europe-France, Germany, Greece, Israel, Italy, the Netherlands, Norway; Sweden; Central Europe-Bulgaria, Lithuania, Poland, Romania, Russia, Ukraine; Asia-PacificAustralia, China, India, Malaysia, New Zealand, Republic of Korea, Singapore, Taiwan, Thailand.
Country income data in gross national income per capita in current US dollars and classifications from the year 2007 (ie, the year ASCEND-HF trial enrollment began) were abstracted from the World Bank. 17 As defined by the World Bank using data from 2007, countries were assigned to 1 of 4 country income categories as defined by the World Bank: high income (>$11 455), upper-middle income ($3706-$11 455), lower-middle income ($936-$3705), and low income (<$936). 18 Country income data were available for all countries in ASCEND-HF, with exception of Taiwan, which was not listed as a separate country. Thus, the current analysis included data from the 29 remaining countries in the trial (N=7064). Acknowledging existence of other grading metrics for social and economic development of a country, World Bank income classifications were cross-referenced with classifications per the United Nations Development Programme 2007 Health Development Index (HDI). 19 Among enrolling countries in ASCEND-HF, application
WHAT IS KNOWN
• Prior heart failure clinical trials have shown that patient profile and clinical outcomes vary markedly with the geographic region of patient enrollment.
• Consistent with trends toward globalization of clinical trials, recent heart failure trials have included patients from both high-income and lower income countries.
WHAT THE STUDY ADDS
• This is the first study to examine the influence of enrolling country income level on heart failure clinical trial end points, protocol completion, and adverse events.
• Enrolling country income level may impact study end points and rates of protocol completion and adverse events, independent of geographic region.
• This study suggests that design of future heart failure clinical trials should be mindful of the specific characteristics of individual enrolling countries, in addition to the broader geographic region.
of HDI classification resulted in identical country groupings as compared with the World Bank classification, thus dedicated analysis by HDI status was not performed.
Study End Points and Definitions
Prespecified end points for the present study included (1) 180-day all-cause death, (2) composite 30-day all-cause death or HF hospitalization, (3) composite 30-day all-cause death or all-cause rehospitalization, and (4) persistent dyspnea (ie, no dyspnea improvement) at 6 and 24 hours. Causes of death and hospitalization within 30 days were adjudicated by an independent blinded clinical events committee (University of Glasgow, Glasgow, Scotland, United Kingdom). To evaluate trial site performance by country income level, protocol noncompletion rate at 180 days was an additional end point. Consistent with a prior analysis, protocol noncompletion was defined as early withdrawal from the study because of withdrawal of consent, lost to follow-up, or protocol deviation. 20 Adverse event rate at 180 days was reported separately. Persistent dyspnea was defined as a binary end point using a patient-reported 7-point categorical Likert scale. A response of markedly worse, moderately worse, minimally worse, no change, or minimally better was defined as persistent dyspnea. Definitions for hospitalization for HF and protocol deviation are provided in Appendix A in the Data Supplement.
Statistical Analysis
Baseline characteristics were compared between country income level groups. Continuous variables were reported as median (25th-75th percentile) and compared using KruskalWallis tests. Categorical variables were presented as frequencies and percentages and compared using the Pearson χ 2 test or the Fisher exact test. Kaplan-Meier event rates for 180-day all-cause death and raw event rates for other end points were reported across groups.
Country income level was prespecified to be examined as both a categorical variable by country income level group and a continuous variable per US $10 000 increase. Unadjusted and adjusted logistic regression models were constructed to evaluate associations between country income level and 30-day end points, persistent dyspnea, and protocol noncompletion. Unadjusted and adjusted Cox models were used to evaluate associations with 180-day all-cause death. To account for potential clustering of patients within countries, multilevel models were used for the primary analyses. Specifically, models used random-intercept multilevel logistic regressions (generalized linear mixed models) and shared frailty Cox regression, each using random effects for country of enrollment. To better discern the influence of geographic region on associations between country income level and study end points, a 3-tiered approach was applied to adjusted models. The base model included adjustment for age, sex, and race. The second model included base model variables plus geographic region. The third model (ie, full model) included variables from the first 2 models plus 13 additional clinical covariates previously used in ASCEND-HF mortality and dyspnea models. [20] [21] [22] Because of the lack of established clinical confounders for protocol noncompletion, the third tier of adjustment was not performed for this end point.
The proportional hazards assumption was tested for the Cox model, and linearity assumptions were tested in all models, and no violations were found. In addition, interaction testing was prespecified to examine (1) potential differential associations between country income level and outcomes across geographic regions and (2) potential differential efficacy of nesiritide by country income level. Multiple imputation was used for missing covariate data; results reflect the combined analysis of 25 imputed datasets. All statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC). Two-tailed P<0.05 was considered statistically significant.
RESULTS

Distribution of Country Income Level
Of the 29 countries with available income data, 14 (48%) were high income, 11 (38%) were upper-middle income, and 4 (14%) were lower-middle income. These groups comprised 3996, 1518, and 1550 patients, respectively ( Figure 1 ). There were no low-income countries. The proportion of countries and patients from each geographic region differed by country income group ( Figure 2 ). For example, North American and Western European countries were exclusively high income and Latin American countries were exclusively upper-middle income.
Patient Characteristics
Baseline patient characteristics differed by income level category (Table 1) . Patients from lower-middle-income countries tended to be younger with lower systolic blood pressure and body mass index. These patients were more likely to have reduced ejection fraction and New York Heart Association class III/IV symptoms before decompensation but less likely to have prior HF hospitalization and many comorbidities, such as prior myocardial infarction, coronary revascularization, cerebrovascular disease, atrial fibrillation/flutter, and chronic lung disease. Despite having the highest proportion patients with reduced ejection fraction, patients from lower-middle-income countries were substantially less likely to receive many guideline-directed medical and device-based therapies for HF with reduced ejection fraction, including angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, β-blockers, and implantable cardioverter-defibrillators. For instance, 28% of patients from high-income countries had an implantable cardioverter-defibrillator at baseline compared with <1% among lower-middle-income patients.
Protocol Completion and Adverse Events
Rates of protocol noncompletion and adverse events at 180 days are displayed in Table 2 . Protocol noncompletion (4.9%) was the most common among high-income countries (P<0.001). Adverse event rates increased with higher country income level, with the highest rate (13.8%) among high-income countries and the lowest rate (3.8%) among lower-middle-income countries (P<0.001). After adjustment for demographics and geographic region, categorical analysis with lower-middle income as the referent group suggested >2-fold greater risk of protocol noncompletion among high-income countries (P=0.033) and similar risk between uppermiddle and lower-middle-income countries (P=0.782; Table 3 ). Increasing continuous country income level was associated with increased likelihood of protocol noncompletion at 180 days after adjustment for demographics but not after adjustment for geographic region.
Trial End Points
Event rates by country income level group are displayed in Table 4 . With exception of 30-day all-cause death, which was comparable across groups, high-income countries and lower-middle-income countries had the highest and lowest rates of study end points, respectively. Event rates showed a stepwise increase with higher country income group. Adjudicated causes of death through 30 days are presented in Table I in the Data Supplement.
Unadjusted and adjusted outcome analyses for trial end points are presented in Table 5 . Compared with patients from lower-middle-income countries, patients from higher income countries carried ≈1.5-to 2-fold higher risk of the composite of 30-day death or allcause hospitalization. These results persisted after progressive multivariable adjustment for demographics, geographic region, and the full adjustment model (full model, all P≤0.042). However, the magnitude of associations changed with stepwise adjustment, where patients from high-income countries carried the highest risk after base adjustment and upper-middle-income patients carried the highest risk after adjustment for geographic region and clinical covariates. In continuous variable analysis, every $10 000 increase in country income level was associated with a 10% greater risk of 30-day all-cause death or all-cause hospitalization (P=0.034). The magnitude of this association remained stable after full multivariable adjustment but was reduced to a statistical trend (P=0.076).
With regard to other clinical and dyspnea end points, there were no statistically significant associations between country income level and outcomes in unadjusted or fully adjusted models. Notably, risk of 180-day all-cause death was similar across the spectrum of country income level.
Country Income Level, Geographic Region, and Nesiritide Efficacy
The association between continuous country income level and the composite of 30-day death or all-cause hospitalization differed by geographic region (P for interaction, 0.032; Figure 3 Data expressed as n (%) or median (25th-75th). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; and PCI, percutaneous coronary intervention.
*Overall, 5401 patients had precise ejection fraction measurement data. All 7064 patients had data for ejection fraction ≥50% or <50%. †Patients (5817) had data available for NYHA class. ‡There were 6519, 6608, 6522, and 6683 total patients with available hemoglobin, sodium, BUN, and creatinine data, respectively. §There were 3761 and 989 patients with available NT-proBNP and BNP data, respectively. 
DISCUSSION
In this global AHF trial, the majority of patients were enrolled from high-income countries, a significant minority of patients were enrolled from middle-income countries, and no patients were enrolled from lowincome countries. Patient profile differed markedly by enrolling country income level with patients from higher income countries tending to have better baseline functional class, higher systolic blood pressure, more comorbidities, and higher uptake of guideline-recommended HF therapies. Adverse events and failure to complete the study protocol were most likely among high-income countries. Although there was no association with 180-day all-cause death, patients from higher income countries carried greater risk of 30-day death or hospitalization, and this relationship persisted despite adjustment for race, geographic region, medication use, and other clinical characteristics. Associations between country income level and 30-day outcomes were similar across geographic regions, with exception of Latin America where country income level was associated with lower risk. Likewise, the ability of nesiritide to improve 30-day outcomes varied by country income level, with reductions in clinical end points among patients from uppermiddle-income countries.
To our knowledge, this is the first published analysis of enrolling country income level on AHF trial performance and patient outcomes. Prior studies from AHF clinical trials have centered on patient differences across broadly defined geographic regions without accounting for characteristics of individual countries. [9] [10] [11] [12] Likewise, although such analyses have consistently found patient profile and event rates to vary widely by global region, they have not investigated specific factors that may mediate such differences. Recognizing that cultural and economic heterogeneity within geographic regions is well established and unaccounted for with simple categorization by region, the present ASCEND-HF analysis offers several strengths that provide granular insight into the potential role of country income in AHF studies. First, acknowledging that multiple classification schemes for social and economic development exist, World Bank data were cross-referenced with the United Nations Development Programme HDI, confirming that country groupings by both criteria were identical. 17, 19 Second, the statistical approach included both categorical and continuous variable outcome analysis to explore the impact of the income cut points defined by the World Bank. Third, analyses included a diverse set of end points, including postdischarge clinical outcomes, patient-reported dyspnea outcomes, and a trial performance outcome defined as protocol noncompletion. Simultaneous assessment of these end points within a single population was done to broadly capture the patient experience by country income level, while also allowing assessment of potential interplay and tradeoffs between patient profile, event rates, and study execution. Lastly, acknowledging that race, geographic region, and country income status may overlap, a 3-tiered stepwise multivariable adjustment strategy was prespecified to explore the independent association with country income. The robust and independent association between country income category and 30-day death or hospitalization persisted after adjustment for race in the base model, additional adjustment for geographic region in the second model, and further adjustment for clinical factors in the third model. In contrast to existing ASCEND-HF data, where 30-and 180-day mortalities were shown to differ by geographic region of enrollment, no independent associations with mortality were seen here. 12 Thus, in aggregate, these collective data from ASCEND-HF strongly suggest that geographic region is not a dependable surrogate for country income status. Rather, country income level may vary within geographic regions and may independently predict clinical trial outcomes.
Prior work has speculated on mechanisms by which geographic region may drive patient heterogeneity within global AHF trials. 8, 23 Potential domains of variation underlying regional differences include patient factors (eg, HF pathophysiology/genetics, race/ethnicity, comorbidities), trial site factors (eg, interpretation of trial selection criteria, data collection and accuracy, protocol adherence), healthcare practice factors (eg, utilization of guideline therapies, physician and patient thresholds for hospital admission/discharge decisions), and healthcare environment factors (eg, physician/ hospital reimbursement incentives, patient access to health care, socioeconomics, medicolegal liability climate). 8, 11 It is notable that while biologic differences in HF across the world have been reported, differences in patient profile and outcomes may be largely mediated by nonbiologic inconsistencies in the HF diagnosis, For 180-d all-cause death, data represent hazard ratios; for all other outcomes, data represent odds ratios. *Adjusted for age, sex, and race. †Adjusted for age, sex, race, and geographic region. ‡Adjusted for age, sex, race, geographic region, body mass index, prior heart failure hospitalization in past 1 y, systolic blood pressure, blood urea nitrogen, serum sodium, smoking status, presence of nocturnal dyspnea, presence of elevated jugular venous pulsation, cerebrovascular disease, history of depression, and background medications (angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, β-blocker, and mineralocorticoid receptor antagonist).
§Persistent dyspnea was defined as a binary outcome using a self-reported 7-point categorical Likert scale as any of the following responses: markedly worse, moderately worse, minimally worse, no change, or minimally better.
ways in which data are recorded, and ways in which HF care is delivered. 24, 25 In the current study, it is notable that associations between country income status and 30-day death or hospitalization were strongly driven by wide variation in rates of rehospitalization. In contrast, risks of 30-and 180-day mortalities were remarkably similar. Collectively, these data generate the hypothesis that preferential access to and use of hospitalization as a care strategy for AHF and other comorbid conditions among higher income countries, rather than disease severity, are predominant drivers of differential rates of hospitalization. Although index hospitalization data for presenting HF signs and symptoms are mixed, the combination of higher rates of prior and subsequent hospitalization with similar downstream risk of death could be compatible with increased availability of hospital resources and lower thresholds for hospitalization among higher income countries. Alternatively, we acknowledge the possibility of hospitalization underreporting among lower income countries but have no objective evidence to support this.
Clinical Trial Implications
Although reflective of the global HF burden and the universal need for improved therapy, the potential adverse consequences of HF trial globalization are becoming increasingly recognized. Rather than a primary intent for inclusive and collaborative research, globalization may be largely driven by relative inability to conduct large trials in high-income countries, where enrollment is consistently slower and the regulatory environment generally more bureaucratic and expensive. 7 Ideally, clinical research should be conducted in populations in proportion to their potential use after therapy approval. 5, 6 Unfortunately, although sponsors may find lower income countries appealing from a regulatory and cost perspective, these countries may be paradoxically more likely to find newly approved therapies prohibitively expensive, and routine uptake may occur only after years of use in wealthier countries. 5, 6 The results of the current study from ASCEND-HF confirm that effects of trial globalization may extend beyond geographic location to the economic development of the individual country. The present results highlight country income level as an additional dimension of variation within trials that may influence end points. Aside from implications for study power calculations, the potential differential efficacy of nesiritide on 30-day outcomes is consistent with prior examples suggesting the proportion of patients from specific countries may impact final results. 26 Thus, in addition to ethical questions about inclusion of patients from lower income countries, globalization has the potential to be problematic for regulators, third-party payers, guideline writers, and practicing clinicians who must judge whether results from global trials are generalizable to their respective populations. 8 Moreover, although the possibility of underreporting among lower income countries must be acknowledged, the present findings suggesting higher rates of protocol noncompletion and adverse events among high-income countries may speak to the relative inefficiency of the clinical trial enterprise in wealthier countries. The combination of slower enrollment, higher costs, and lower likelihood of completing the study protocol confirms the complex challenges facing clinical trials in high-income countries and the persistent need for major improvements. Although the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggested quality control issues may be more apparent outside of highincome countries, the protocol completion and adverse event data presented here suggest that a unique set of trial performance concerns may apply to high-income countries. 14, 26 Nonetheless, the collective findings from ASCEND-HF and TOPCAT suggest that attention toward trial conduct may be better directed toward characteristics of the individual country, rather than the broader geographic region. The best approach for anticipating site-and country-specific challenges regarding study execution and end points is unclear, but a pretrial registry has been proposed and may carry advantages.
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Limitations
First, although rigorous multivariate modeling with prespecified covariates was performed, the possibility of residual confounding exists and the retrospective observational nature of this study prohibits definitive determination of cause-effect relationships. Second, although inconsistent with the aims of this hypothesisgenerating work, adjustment for multiple comparisons may have modified results. Third, the distribution of countries within ASCEND-HF included no low-income countries, thus conclusions of the current analysis may not extend beyond high-and middle-income countries. Fourth, although objective World Bank data were crossreferenced with HDI data for categorizing countries, both may be imperfect surrogates for social and economic development, and it is possible that such characteristics could vary by study sites within individual countries (eg, rural versus urban settings).
Conclusions
In this global AHF trial, the majority of patients were enrolled from high-income countries, a significant minority of patients were from upper-middle-income and lower-middle-income countries, and no patients were from low-income countries. Patient characteristics and uptake of guideline-directed therapies varied by enrolling country income level. Patients from higher income countries had lower rates of protocol completion, higher rates of adverse events, and worse 30-day outcomes that persisted after adjustment for race, geographic region, and clinical factors. Mortality rates were similar and differences in clinical outcomes were driven by increased rates of rehospitalization in higher income countries. Variation in enrolling country income level is a challenge to be considered in global HF trials that may influence study end points and trial performance independent of geographic region.
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